State-dependent increase in the levels of neurotrophin-3 and neurotrophin-4/5 in patients with bipolar disorder: A meta-analysis

Tseng, Ping‐Tao; Chen, Yen‐Wen; Tu, Kun-Yu; Wang, Hung-Yu; Chung, Wen‐Hsin; Wu, Ching-Kuan; Hsu, Shih‐Pin; Kuo, Hung-Chang; Lin, Pao‐Yen

doi:10.1016/j.jpsychires.2016.05.009

Cited by 23 publications

(13 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…progression (Grande et al, 2016;Young et al, 2018). For the molecules, due to the large volume of published data regarding inflammation, oxidative stress, and decreased neurotropic factors in BD, findings from meta-analytic studies were included (Andreazza et al, 2008;Brown et al, 2014;Fernandes et al, 2015;Ghidoni et al, 2008;Goldsmith et al, 2016;Modabbernia et al, 2013;Rao et al, 2017;Tseng et al, 2016;Wang and Miller, 2018). For BD, original articles retrieved using the following search terms (Atagi et al, 2015;Blasko et al, 2006;Bossu et al, 2011;Galimberti et al, 2008;Galimberti et al, 2009;Hu et al, 2010;Kittel-Schneider et al, 2014;Martinez et al, 2008;Miller et al, 2013;Rainero et al, 2009;Rentzos et al, 2006a;Rentzos et al, 2006b;Ventriglia et al, 2013): "bipolar disorder AND inflammation", "bipolar disorder AND oxidative stress", "bipolar disorder AND neurotrophic factor" were included.…”

Section: Shared Biological Pathways May Underlie Both Bd and Ftdmentioning

confidence: 99%

“…The same search strategy was used for FTD, where the word "bipolar disorder" was replaced by "frontotemporal dementia". For both diseases, findings of studies measuring inflammatory biomarkers and neurotrophic factors in human peripheral tissue or CSF were included (Atagi et al, 2015;Blasko et al, 2006;Bossu et al, 2011;Fernandes et al, 2015;Galimberti et al, 2008;Galimberti et al, 2009;Goldsmith et al, 2016;Hu et al, 2010;Kittel-Schneider et al, 2014;Miller et al, 2013;Modabbernia et al, 2013;Rainero et al, 2009;Rao et al, 2017;Rentzos et al, 2006a;Rentzos et al, 2006b;Tseng et al, 2016;Ventriglia et al, 2013;Wang and Miller, 2018). Concerning oxidative stress markers, investigations measuring these alterations in human post-mortem brains were also included (Andreazza et al, 2008;Brown et al, 2014;Martinez et al, 2008).…”

Section: Shared Biological Pathways May Underlie Both Bd and Ftdmentioning

confidence: 99%

“…Age at onset Peak 20 to 40 (Yassa et al, 1988) 45 to 65 (Snowden et al, 2002) Duration (years) 3.2 to 10.4 (Medeiros et al, 2016;Zhang et al, 2017) Average of 6 (Young et al, 2018) Progression Varies widely across mood episodes (Grande et al, 2016) Fast (Young et al, 2018) Inflammation Cytokines and Cytokine receptors: IL-1, IL-4, IL-6, IL-10 sIL-2R, IL-1β, and sIL-2R, sIL-6R (Goldsmith et al, 2016;Wang and Miller, 2018;Modabbernia et al, 2013) Cytokines: IL-6, IL-11, IL12, IL-15, IL-17, IL-23 (Rentzos et al 2006;Galimberti et al 2008;Rainero et al 2009;Hu et al 2010;Bossù et al, 2011) Chemokines: TNF-α, sTNFR1 (Modabbernia et al, 2013) Chemokines: TBK1, TNF-α, MCP-1 (Miller et al 2013;Blasko et al 2006) Others: progranulin Kittel-Schneider et al, 2014) Others: progranulin, TREM2 (Ghidoni et al, 2008;Atagi et al 2015) Neurotrophic factors BDNF, NGF, IGF-1, NT-3 and NT-4/5 (Fernandes et al, 2015;Tseng et al, 2016;Tu et al, 2016;Rao et al, 2017) BDNF and NGF (Ventriglia et al 2013;Blasko et al 2006;Galimberti et al 2009) Oxidative damage…”

Section: Bd Ftdmentioning

confidence: 99%

See 2 more Smart Citations

A review on shared clinical and biological aspects of bipolar disorder and frontotemporal dementia

Nascimento¹,

Villela²,

Rodriguez³

et al. 2018

Preprint

View full text Add to dashboard Cite

Mental disorders are highly prevalent and important causes of medical burden worldwide. Co-occurrence of neurological and psychiatric symptoms are observed among mental disorders, representing a challenge for their differential diagnosis. Psychiatrists and neurologists have faced challenges in diagnosing older adults presenting behavioral changes. This is the case for early frontotemporal dementia (FTD) and late bipolar disorder. Early FTD is characterized by behavioral or language disturbances in the absence of cognitive symptoms. Consequently, patients with the behavioral subtype of FTD (bv-FTD) can be initially misdiagnosed as having a psychiatric disorder, typically depression or bipolar disorder (BD). Bipolar disorder is associated with a higher risk of dementia in older adults and cognitive impairment, where a subset of patients presents a neuroprogressive pattern during the disease course. Clinical similarities between BD and bv-FTD raise the question whether common molecular pathways might explain shared clinical symptoms. In fact, studies have also shown presence of molecular signatures related to bv-FTD in BD patients. Here, we reviewed existing data on clinical and molecular similarities between BD and FTD and propose biological pathways to be further investigated as common or specific markers of BD and FTD.

show abstract

Section: Shared Biological Pathways May Underlie Both Bd and Ftdmentioning

confidence: 99%

Section: Shared Biological Pathways May Underlie Both Bd and Ftdmentioning

confidence: 99%

Section: Bd Ftdmentioning

confidence: 99%

See 1 more Smart Citation

A review on shared clinical and biological aspects of bipolar disorder and frontotemporal dementia

Nascimento¹,

Villela²,

Rodriguez³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…Studies about the possible connections between NT-3 and mood disorders are still controversial. Hock et al found increased cerebrospinal fluid levels of NT-3 in elderly patients with depression compared with mentally healthy control subjects (Hock et al 2000 ), and other studies also showed increased NT-3 level in bipolar disorders (Loch et al 2015 ; Tseng et al 2016 ). In contrast, a study demonstrated the opposite result (Otsuki et al 2008 ), while Munkholm et al found no difference in NT-3 level in bipolar disorder patients compared with controls (Munkholm et al 2014 ).…”

Section: Introductionmentioning

confidence: 98%

The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections

et al. 2019

View full text Add to dashboard Cite

Cardiovascular (CV) diseases and mood disorders are common public health problems worldwide. Their connections are widely studied, and the role of neurotrophins (NTs) is already supposed in both conditions. However, data in the literature of clinical aspects are sometimes controversial and no reviews are available describing possible associations between CV risk and mood disorders based on NTs. The mostly studied NT is brain-derived neurotrophic factor (BDNF). Decreased level of BDNF is observed in depression and its connection to hypertension has also been demonstrated with affecting the arterial baroreceptors, renin–angiotensin system and endothelial nitric oxide synthase. BDNF was also found to be the predictor of CV outcome in different patient populations. Other types of human NT-s, such as nerve growth factor, neurotrophin 3 and neurotrophin 4 also seem to have both psychopathological and CV connections. Our aim was to overview the present knowledge in this area, demonstrating a new aspect of the associations between mood disorders and CV diseases through the mediation of NTs. These findings might enlighten new psychosomatic connections and suggest new therapeutic targets that are beneficial both in respect of mood disorders and CV pathology.

show abstract

“…Impairment of neuroplasticity may also be involved in the pathophysiology of bipolar disorder and potentially contribute to neuroprogressive changes during the course of the illness . Brain‐derived neurotrophic factor (BDNF) is an important regulatory mediator of cellular plasticity , and levels of BDNF in peripheral blood appear altered in bipolar disorder along with other neurotrophins such as neurotrophin‐3 (NT‐3) . Mitochondrial dysfunction and oxidative stress have increasingly been speculated to be involved in the pathophysiology of bipolar disorder supported by findings of alterations of oxidative stress marker levels in peripheral blood, particularly involving oxidative stress to DNA and RNA .…”

Section: Introductionmentioning

confidence: 99%

A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder

Munkholm

Vinberg

Pedersen

et al. 2018

Acta Psychiatr Scand

View full text Add to dashboard Cite

HE, Ekstrøm CT, Kessing LV. A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder.Objective: Diagnosis and management of bipolar disorder (BD) are limited by the absence of available laboratory tests. We aimed to combine data from different molecular levels and tissues into a composite diagnostic and state biomarker. Methods: Expression levels of 19 candidate genes in peripheral blood, plasma levels of BDNF, NT-3, IL-6 and IL-18, leukocyte counts, and urinary markers of oxidative damage to DNA and RNA were measured in 37 adult rapid-cycling patients with BD in different affective states during a 6-to 12-month period and in 40 age-and gender-matched healthy individuals in a longitudinal, repeated measures design comprising a total of 211 samples. A composite biomarker was constructed using data-driven variable selection. Results: The composite biomarker discriminated between patients with BD and healthy control individuals with an area under the receiver operating characteristic curve (AUC) of 0.83 and a sensitivity of 73% and specificity of 71% corresponding with a moderately accurate test. Discrimination between manic and depressive states had a moderate accuracy, with an AUC of 0.82 and a sensitivity of 92% and a specificity of 40%. Conclusion: Combining individual biomarkers across tissues and molecular systems could be a promising avenue for research in biomarker models in BD. Significant outcomes• For the first time, we explored the potential of combining data from different molecular levels and tissues into a composite marker of diagnosis and state.• The composite biomarker discriminated moderately well between patients with bipolar disorder and healthy control individuals and between a manic and a depressed state. Limitations• The sample size was modest considering the use of a split-sample design in developing and testing the composite marker.• Medication and differences in behaviour might have influenced the measured analytes. • Our study population consisted of patients with rapid-cycling bipolar disorder and results may therefore not be generalizable to all patients with bipolar disorder.

show abstract

State-dependent increase in the levels of neurotrophin-3 and neurotrophin-4/5 in patients with bipolar disorder: A meta-analysis

Cited by 23 publications

References 47 publications

A review on shared clinical and biological aspects of bipolar disorder and frontotemporal dementia

A review on shared clinical and biological aspects of bipolar disorder and frontotemporal dementia

The role of neurotrophins in psychopathology and cardiovascular diseases: psychosomatic connections

A multisystem composite biomarker as a preliminary diagnostic test in bipolar disorder

Contact Info

Product

Resources

About